A lipid index for risk of hyperlipidemia caused by anti-retroviral drugs

In this study, we propose a pharmacological lipid index to estimate the risk of hyperlipidemia caused by anti-retroviral drugs. Lipid droplets were stained in cells treated with anti-retroviral drugs and cyclosporin A. Signal intensities of lipid droplets were plotted against the drug concentrations to obtain an isodose of 10 μM of cyclosporin A, which we call the Pharmacological Lipid Index (PLI). The PLI was then normalized by EC50. PLI/EC50 values were low in early proteinase inhibitors and the nucleoside reverse transcriptase inhibitor, d4T, indicating high risk of hyperlipidemia, which is consistent with previous findings of hyperlipidemia. In contrast, there are few reports of hyperlipidemia for drugs with high PLI/EC50 scores. Data suggests that PLI/EC50 is a useful index for estimating the risk of hyperlipidemia.PMID:38272319 | DOI:10.1016/j.antiviral.2024.105819

Source: Antiviral Research - January 25, 2024 Category: Virology Authors: Mari Shimura Nobuyo Higashi-Kuwata Asuka Fujiwara Mai Taniguchi Takayuki Ichinose Fumie Hamano Masaaki Uematsu Takato Inoue Satoshi Matsuyama Takahiro Suzuki Arun K Ghosh Hideo Shindou Takao Shimuzu Hiroaki Mitsuya Source Type: research